![Timothy Cowper](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Timothy Cowper
Direttore Finanziario/CFO presso VERNALIS
Patrimonio netto: 234 565 $ in data 30/06/2024
Posizioni attive di Timothy Cowper
Società | Posizione | Inizio | Fine |
---|---|---|---|
OXFORD NANOPORE TECHNOLOGIES PLC | Direttore operativo | 22/01/2024 | - |
Comptroller/Controller/Auditor | 01/01/2012 | 01/01/2013 | |
Direttore/Membro del Consiglio | 01/01/2012 | 10/06/2024 | |
Direttore Finanziario/CFO | 01/01/2012 | 22/01/2024 | |
VERNALIS | Direttore Finanziario/CFO | - | - |
Storia della carriera di Timothy Cowper
Precedenti posizioni note di Timothy Cowper
Società | Posizione | Inizio | Fine |
---|---|---|---|
Celltech Group Plc
![]() Celltech Group Plc BiotechnologyHealth Technology Celltech Group Plc was one of the leading European biotechnology company which is engaged in discovery and development of innovative drugs. The company was located in Slough, United Kingdom. | Comptroller/Controller/Auditor | 01/01/1991 | 01/01/1997 |
Sterilox Medical Ltd. | Comptroller/Controller/Auditor | - | - |
Formazione di Timothy Cowper
University of Sussex | Undergraduate Degree |
Statistiche
Distribuzione geografica
Regno Unito | 6 |
Posizioni
Comptroller/Controller/Auditor | 3 |
Director of Finance/CFO | 2 |
Director/Board Member | 1 |
Settori
Health Technology | 3 |
Electronic Technology | 2 |
Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
OXFORD NANOPORE TECHNOLOGIES PLC | Electronic Technology |
Aziende private | 3 |
---|---|
Celltech Group Plc
![]() Celltech Group Plc BiotechnologyHealth Technology Celltech Group Plc was one of the leading European biotechnology company which is engaged in discovery and development of innovative drugs. The company was located in Slough, United Kingdom. | Health Technology |
Ligand UK Ltd.
![]() Ligand UK Ltd. Pharmaceuticals: MajorHealth Technology Ligand UK Ltd. is a commercial stage pharmaceutical company. Its products include Tuzistra XR, targeting the U.S. prescription cough-cold market, Moxatag, a once-a-day formulation of the antibiotic and amoxicillin, and frovatriptan, used for the acute treatment of migraine. It also develops and commercializes multiple novel products focused on the U.S. prescription cough-cold market. The company was founded by Keith G. McCullagh and Andre L. Lamotte in 1988 and is headquartered in Winnersh, the United Kingdom. | Health Technology |
Sterilox Medical Ltd. |
- Borsa valori
- Insiders
- Timothy Cowper
- Esperienza